| Teriggi Ciccone, MD | |
|
41 Highland Ave, Winchester, MA 01890-1446 | |
| (781) 756-7273 | |
| (781) 756-7274 |
| Full Name | Teriggi Ciccone |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 41 Highland Ave, Winchester, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376554584 | NPI | - | NPPES |
| 2078431 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 220175 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Winchester Hospital | Winchester, MA | Hospital |
| Beth Israel Deaconess Hospital - Milton | Milton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Winchester Physician Associates Inc | 4486540994 | 161 |
| Bid-milton Physician Associates Inc | 7416375399 | 46 |
| Beth Israel Deaconess Medical Center Inc | 8123936119 | 83 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316987993 PECOS PAC ID: 4486567104 Enrollment ID: O20040105000227 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952358533 PECOS PAC ID: 6305749987 Enrollment ID: O20040130000354 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Winchester Emergency Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831131473 PECOS PAC ID: 5799755385 Enrollment ID: O20040820000555 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Winchester Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184606865 PECOS PAC ID: 4486540994 Enrollment ID: O20060215000452 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952358533 PECOS PAC ID: 6305749987 Enrollment ID: O20130606000720 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Bid-milton Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164060778 PECOS PAC ID: 7416375399 Enrollment ID: O20200909000678 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538774443 PECOS PAC ID: 4486567104 Enrollment ID: O20201029002622 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Teriggi Ciccone, MD 41 Highland Ave, Winchester, MA 01890-1446 Ph: (781) 756-7273 | Teriggi Ciccone, MD 41 Highland Ave, Winchester, MA 01890-1446 Ph: (781) 756-7273 |
News Archive
Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP).
Researchers at Yale School of Medicine and collaborators have successfully used ozone to disinfect the respirator masks used by healthcare workers to protect against respiratory diseases such as coronavirus disease 2019 (COVID-19).
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.
G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
› Verified 5 days ago
Calvin A Lee, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 41 Highland Ave, Winchester, MA 01890 Phone: 508-580-1670 | |
Dr. Dana I. Zitkovsky, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 41 Highland Ave, Winchester Hospital Emergency Department, Winchester, MA 01890 Phone: 781-756-2000 | |
Brian Cruz, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 41 Highland Ave, Winchester, MA 01890 Phone: 781-756-7273 Fax: 781-756-7274 | |
Shahrouz Hekmatpour, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 41 Highland Ave, Winchester, MA 01890 Phone: 781-729-2000 Fax: 781-756-7274 | |
Joseph L Chang, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 41 Highland Ave, Winchester, MA 01890 Phone: 781-729-9000 | |
Dean Tully, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 41 Highland Ave, Winchester, MA 01890 Phone: 781-756-2000 |